AgomAb Therapeutics NV (NASDAQ:AGMB – Get Free Report) was the target of a large growth in short interest during the month of April. As of April 30th, there was short interest totaling 755,022 shares, a growth of 74.3% from the April 15th total of 433,265 shares. Approximately 2.1% of the company’s stock are short sold. Based on an average daily trading volume, of 172,021 shares, the days-to-cover ratio is presently 4.4 days.
AgomAb Therapeutics Stock Performance
Shares of AGMB traded down $0.14 during mid-day trading on Monday, hitting $10.41. 1,204 shares of the company’s stock traded hands, compared to its average volume of 160,238. AgomAb Therapeutics has a 1 year low of $9.00 and a 1 year high of $17.45. The business has a 50-day simple moving average of $11.74.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently issued reports on AGMB shares. Leerink Partners started coverage on AgomAb Therapeutics in a research report on Tuesday, March 3rd. They set an “outperform” rating and a $36.00 target price for the company. Morgan Stanley initiated coverage on AgomAb Therapeutics in a research note on Tuesday, March 3rd. They issued an “overweight” rating and a $28.00 target price for the company. Wall Street Zen upgraded AgomAb Therapeutics to a “hold” rating in a research report on Tuesday, February 17th. Zacks Research upgraded AgomAb Therapeutics to a “hold” rating in a research report on Wednesday, March 4th. Finally, JPMorgan Chase & Co. initiated coverage on AgomAb Therapeutics in a research report on Tuesday, March 3rd. They set an “overweight” rating and a $32.00 price target for the company. Three equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $32.00.
About AgomAb Therapeutics
AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.
AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.
Recommended Stories
- Five stocks we like better than AgomAb Therapeutics
- Consumer-Driven Stocks Boost Buybacks, Including Visa’s $20B Plan
- Iran Ceasefire Trade: 3 Energy Stocks to Own if Oil Falls to $80
- Willing and Abel: Berkshire’s New CEO Makes Huge Portfolio Changes in Q1
- Insider Buying Says Upstart Isn’t Down for the Count
Receive News & Ratings for AgomAb Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AgomAb Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
